Parexel International (ma) Corporation
Location
Massachusetts
Founded
1983-02-28
Website
Risk Signals
451 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Parexel International (ma) Corporation
Live alerts from global media, monitored by Business Radar
2025-03-06 (expresspharma.in)
Jeff Bernstein joins Parexel's Board of Directors -
Jeff Bernstein succeeds Michael Bruun as part of a planned rotation
Read more
2025-03-05 (morningstar.com)
Parexel Announces Updates to Board of Directors | Morningstar
Jeff Bernstein, Partner, Private Equity, Goldman Sachs Asset Management, and Co-Head, Goldman Sachs Healthcare Private Equity Investing, joins as new Director.
Read more
2024-10-22 (globenewswire.com)
Parexel Names Keri Mattox Chief Business Officer
DURHAM, N.C., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Parexel , one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced the appointment of Keri Mattox to the newly created role of Chief Business Officer. In
Read more
2024-10-01 (globenewswire.com)
Nxera Pharma Appoints Experienced Commercial R&D Executive Makoto Sugita as Chief Medical Officer and President of Nxera Pharma Japan
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial...
Read more
2024-09-04 (globenewswire.com)
Parexel Strengthens Real World Research Offering
Mike D’Ambrosio appointed as Senior Vice President, Global Head, Real World Research, reflecting the company’s commitment to an evidence-based approach in...
Read more
2024-03-25 (eletsonline.com)
Parexel Announces CEO Succession Plan: Peyton Howell to Succeed Jamie Macdonald - Elets eHealth
Parexel, a prominent clinical research organization (CRO), has unveiled its CEO succession plan, marking a significant transition in its leadership.
Read more
2024-03-04 (fiercebiotech.com)
Parexel co-founder Josef von Rickenbach to end 35-year run as CEO
Josef von Rickenbach, the chairman and CEO of Parexel, will retire | Josef von Rickenbach, the chairman and CEO of Parexel, will retire from his daily CEO duties at the CRO after a 35-year tenure, passing the baton to Jamie Macdonald, who was previously the helmsman of INC Research.
Read more
2023-12-13 (ottawasun.com)
ACRO Announces 2024 Officers and New Members
WASHINGTON — ACRO today announced that its Board of Directors has elected Peyton Howell, Chief Operating & Growth Officer at Parexel, as Chair of the...
Read more
2023-07-21 (appliedclinicaltrialsonline.com)
People and Business News – 7/23
The latest people and business news from the past month, all in one place.
Read more